BOSTON, Nov. 16, 2016 /PRNewswire/ -- Mapi, the market leader in Prospective Real-World Evidence generation, Health Research Analytics and Evidence Synthesis announces their collaboration with Saama Technologies, Inc., the leading Big Data solutions company.
The initial phase of this partnership establishes a framework to integrate Saama's extensive experience bringing comprehensive data and advanced analytics solutions with Mapi's industry leading expertise in qualitative and quantitative analytics; both Mapi and Saama are investing in synchronization of processes, standards and technology enablement for a seamless experience to our mutual customers. The joint offering enables access to state of the art data mining, visualization tools and expertise to manage Data Oceans with Mapi's unmatched analytics and insight expertise in Health Economics, Patient Outcomes, Adherence, Epidemiology, Drug Safety and Patient Engagement Patient Perspectives. James Karis, Mapi's CEO, commented, "This new partnership provides our customers with the benefit of Mapi's over 40 years in Patient-Centered research combined with the ability to more efficiently and effectively use technology to interpret and analyze real time data from international studies with higher data quality and speed than has previously been possible." Saama's Fluid Analytics™ for Life Sciences delivers proven services, methodology and technology for rapidly orchestrating and analysing large volumes of data. Their hybrid approach blends technology acceleration with human expertise and industry-specific data assets, enabling better business outcomes with speed and specificity. Now global pharmaceutical companies can make better clinical decisions before and after a product is introduced to the market, ultimately bringing safer, more effective products to patients in less time. Additionally, Mapi and Saama have already initiated an expert engagement process to work with Mapi's industry leading Real-World Evidence teams to provide patient perspectives through social media mining. Drug regulatory agencies and health care payers are now considering social media information as part of their decision making process. The combined solution is designed to identify the key patterns in social media content to provide insight on patient perspective and experience to help health care companies meet these new expectations.